Trastuzumab Deruxtecan

Preferred Label : Trastuzumab Deruxtecan;

NCIt synonyms : Fam-trastuzumab Deruxtecan-nxki; WHO 10516; T-DXd;

NCIt definition : An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of trastuzumab deruxtecan, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect.;

UNII : 5384HK7574;

CAS number : 1826843-81-5;

Drug name : Enhertu;

Molecule name : DS-8201a; DS-8201;

NCI Metathesaurus CUI : CL509598;

Codes from synonyms : 3590;

Détails

Origin ID

C128799;

UMLS CUI

C4726900;

Currated CISMeF NLP mapping
- Trastuzumab deruxtecan [SMS substance]
- Trastuzumab deruxtecan (substance) [SNOMED CT concept]
- trastuzumab deruxtecan [MeSH Supplementary Concept]
- trastuzumab deruxtecan [MeSH concept]
Manual BTNT mappings - CISMeF
- trastuzumab deruxtecan [ATC Code]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing trastuzumab deruxtecan (medicinal product) [SNOMED CT concept]
- Trastuzumab deruxtecan (substance) [SNOMED CT concept]
- trastuzumab deruxtecan [MeSH Supplementary Concept]
- trastuzumab deruxtecan [ATC Code]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Receptor Tyrosine-Protein Kinase erbB-2 [NCIt concept]
is_component_of_chemotherapy_regimen
- Trastuzumab Deruxtecan Regimen [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients